RELATED PRODUCTS NOT AVAILABLE
For the superficial femoral and full popliteal artery, the LifeStent™ Vascular Stent has a history of proven performance
The LifeStent™ 5F Vascular Stent System offers the same clinically-proven advanced helical stent design as the LifeStent™ Vascular Stent on a low profile, 5F delivery system. The LifeStent™ 5F delivery system offers dual speed thumbwheel deployment with a tri-axial catheter that is designed for ease of use, deployment control, and precise placement accuracy.2
The LifeStent™5F Vascular Stent System is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and popliteal artery. The LifeStent™ 5F Vascular Stent System is available in 5 mm, 6 mm, and 7 mm diameters; and 20 mm to 170 mm in length.
The LifeStent™ 5F Vascular Stent System features the GeoAlign™ Marking System, which is a simple-to-use, non-radiopaque ruler on the catheter shaft. The GeoAlign™ Marking System is featured on all Bard 5F ProSeries™ products. The GeoAlign™ Marking System is designed to facilitate repeatable catheter alignment at the lesion and to increase procedure efficiency by minimising fluoroscopy exposure.3
1 Commercially available as of December 2023
2 Based on physician ratings during animal testing. May not be indicative of clinical performance. Data on file at Bard Peripheral Vascular, Inc., Tempe, AZ.
3 The GeoAlign™ Marking System provides an approximation that may not be an exact representation of the distance traveled intravascularly and should be confirmed under fluoroscopy.
4 Freedom from TLR at 3 years: 75.5% LifeStent™ Vascular Stent arm (n=134), 41.8% PTA arm (n=72), p LifeStent™ Vascular Stent in 6 mm and 7 mm diameters and lengths of 40-80 mm. The LifeStent™ 5 mm stent diameter and LifeStent™ 5F delivery system were not included in these clinical studies.
5 Primary Patency at 2 years: 64.2% LifeStent™ Vascular Stent arm (n=89), 31.3% PTA arm (n=94), p=0.0001. Patency rates calculated when provisional stenting is considered TLR. Kaplan-Meier analysis with Mantel-Cox log-rank test. The study included LifeStent™ Vascular Stent in 6 mm, 7 mm and 8 mm diameters and lengths of 20-170 mm. The LifeStent™ 5 mm stent diameter and LifeStent™ 5F delivery system were not included in these clinical studies.
6 Primary Patency at 12 months: 81.5% all lesion lengths (n=53). This study included LifeStent™ Vascular Stent in 6 mm and 7 mm diameters and lengths of 20-200 mm. The LifeStent™ 5 mm stent diameter and LifeStent™ 5F delivery system were not included in these clinical studies.